Free Trial

NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma logo
$22.56 -0.85 (-3.63%)
Closing price 03/26/2025 04:00 PM Eastern
Extended Trading
$22.38 -0.17 (-0.78%)
As of 03/26/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NAMS vs. ASND, SRPT, PCVX, QGEN, ROIV, RVMD, LNTH, LEGN, TGTX, and BBIO

Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

NewAmsterdam Pharma vs.

Ascendis Pharma A/S (NASDAQ:ASND) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.

Ascendis Pharma A/S received 421 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.30% of users gave NewAmsterdam Pharma an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

CompanyUnderperformOutperform
Ascendis Pharma A/SOutperform Votes
447
66.82%
Underperform Votes
222
33.18%
NewAmsterdam PharmaOutperform Votes
26
96.30%
Underperform Votes
1
3.70%

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S presently has a consensus target price of $204.64, indicating a potential upside of 29.29%. NewAmsterdam Pharma has a consensus target price of $43.33, indicating a potential upside of 92.08%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
NewAmsterdam Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

NewAmsterdam Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$363.64M26.42-$409.12M-$7.10-22.29
NewAmsterdam Pharma$45.56M54.38-$176.94M-$2.60-8.68

Ascendis Pharma A/S has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.

NewAmsterdam Pharma has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-104.54% N/A -39.23%
NewAmsterdam Pharma N/A N/A N/A

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.21 beat Ascendis Pharma A/S's score of 1.02 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NewAmsterdam Pharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

NewAmsterdam Pharma beats Ascendis Pharma A/S on 11 of the 17 factors compared between the two stocks.

Remove Ads
Get NewAmsterdam Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAMS vs. The Competition

MetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.48B$6.90B$5.62B$8.13B
Dividend YieldN/A2.73%4.56%4.00%
P/E Ratio-8.687.1824.5419.09
Price / Sales54.38226.87386.7694.71
Price / CashN/A65.6738.1634.64
Price / Book6.456.486.974.36
Net Income-$176.94M$142.41M$3.20B$247.23M
7 Day Performance-6.27%-2.89%-2.19%-0.34%
1 Month Performance7.89%-4.52%3.14%-3.60%
1 Year Performance-0.62%-8.69%11.39%2.01%

NewAmsterdam Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAMS
NewAmsterdam Pharma
2.3534 of 5 stars
$22.56
-3.6%
$43.33
+92.1%
-0.7%$2.48B$45.56M-8.684Short Interest ↑
Positive News
High Trading Volume
ASND
Ascendis Pharma A/S
2.946 of 5 stars
$168.84
+10.4%
$202.36
+19.9%
+5.5%$10.25B$363.64M-23.781,017Positive News
High Trading Volume
SRPT
Sarepta Therapeutics
4.8507 of 5 stars
$101.35
+4.3%
$170.41
+68.1%
-43.2%$9.83B$1.90B81.081,314
PCVX
Vaxcyte
2.0514 of 5 stars
$75.23
+1.2%
$147.50
+96.1%
+1.7%$9.69BN/A-16.35160Positive News
QGEN
Qiagen
3.6996 of 5 stars
$39.85
+0.9%
$47.71
+19.7%
-4.7%$8.84B$1.98B110.956,030Short Interest ↑
ROIV
Roivant Sciences
2.3562 of 5 stars
$10.85
+1.8%
$18.08
+66.7%
+3.6%$7.74B$122.59M-72.33860Insider Trade
Positive News
RVMD
Revolution Medicines
4.1302 of 5 stars
$39.13
+0.0%
$66.31
+69.5%
+25.7%$7.27B$742,000.00-10.90250Positive News
LNTH
Lantheus
4.277 of 5 stars
$102.76
+1.6%
$132.86
+29.3%
+67.5%$7.04B$1.53B17.10700Analyst Revision
LEGN
Legend Biotech
2.9144 of 5 stars
$37.94
+2.0%
$79.17
+108.7%
-38.0%$6.93B$627.24M-39.941,800Short Interest ↓
Positive News
TGTX
TG Therapeutics
3.0477 of 5 stars
$41.06
+0.5%
$40.67
-1.0%
+164.2%$6.45B$329.00M-410.56290Positive News
BBIO
BridgeBio Pharma
4.6889 of 5 stars
$33.01
+0.1%
$51.55
+56.2%
+21.3%$6.28B$221.90M-11.58400Analyst Forecast
Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:NAMS) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners